Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07046559 | A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants | PHASE1 | RECRUITING | 104 | — | — | May 13, 2025 | Sep 1, 2027 | Mar 3, 2026 | 1 | United Kingdom |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Part A Cohort 1: Single-Ascending Dose (SAD)- LY4066708 | EXPERIMENTAL | LY4066708 administered by intravenous (IV) injection |
| Part A Cohort 2: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 3A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by subcutaneous (SC) injection |
| Part A Cohort 3B: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by SC injection |
| Part A Cohort 4: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 5: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 5A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 6A: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part A Cohort 6: SAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 1: Multiple-Ascending Dose (MAD)- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 2: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 3: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Part B Cohort 4: MAD- LY4066708 | EXPERIMENTAL | LY4066708 administered by IV injection |
| Placebo | PLACEBO_COMPARATOR | Placebo administered by IV injection |
| Placebo- Part A Cohort 3A and Part A Cohort 3B. | PLACEBO_COMPARATOR | Placebo administered by SC injection |
| Name | Type | Description |
|---|---|---|
| LY4066708 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Japanese Participants Only: To qualify as a participant of first-generation Japanese origin, the participant, the participant's ...